[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604459":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":32,"locations":39,"responsibleParty":64,"collaborators":66,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":26,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":55,"whyStopped":26,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Prescreen Based bDMARD Stategic Treatment Group","EXPERIMENTAL","Strategic groups: This group patients prescreen to various biologics (such as Adalimumab (Humira), Etanercept (Enbrel), Certolizumab pegol (Cimzia) Golimumab (Simponi), Ustekinumab (Stelara),Secukinumab (Cosentyx) Ixekizumab (Taltz),Bimekizumab (Bimzelx), Brodalumab (Lumicef)) on their immune cells and choose the most proper biologics according to a set of biomarkers for individual psoriasis patient before starting the treatment",[13,14],"Diagnostic Test: Prescreen platform","Biological: biologics treatment",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard bDMARD Treatment Group","ACTIVE_COMPARATOR","This group patients receive biologics treatment (such as Adalimumab (Humira), Etanercept (Enbrel), Certolizumab pegol (Cimzia) Golimumab (Simponi), Ustekinumab (Stelara),Secukinumab (Cosentyx) Ixekizumab (Taltz),Bimekizumab (Bimzelx), Brodalumab (Lumicef)) according to present guideline without individuals immune cells screen.",[14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIAGNOSTIC_TEST","Prescreen platform","Different biomarkers on PsO, PsA and paradoxical PsA",[9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"BIOLOGICAL","biologics treatment","All psoriasis patients are receiving biologics treatment",[9,16],[33],{"name":34,"role":35,"phone":36,"phoneExt":37,"email":38},"James Yen, MD PhD","CONTACT","886-4-23592525","5303 or 5301","vernayen@yahoo.com.tw",[40,53],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":44,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":26},"Taichung Veterans Hospital","NOT_YET_RECRUITING","Taichung","Taiwan","407219","TW",{"type":48,"coordinates":49},"Point",[50,51],120.6839,24.1469,{"lat":51,"lon":50},{"facility":54,"status":55,"city":43,"state":44,"zip":56,"country":44,"countryCode":46,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"Taichung Vertenans General Hospital","RECRUITING","886",{"type":48,"coordinates":58},[50,51],{"lat":51,"lon":50},[61],{"name":62,"role":35,"phone":36,"phoneExt":63,"email":38},"James Yen, PhD","5301",{"type":65,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[67,69,71,73],{"name":68,"class":6},"Chang Gung Memorial Hospital",{"name":70,"class":6},"Chung Shan Medical University",{"name":72,"class":6},"Far Eastern Memorial Hospital",{"name":74,"class":6},"China Medical University Hospital","100604459","phase-4-a-multi-center-rct-clinical-trial-on-personalized-precision-medicine-for-patients-with-psoriasis-and-psoriatic-arthritis-and-investigation-on-cardiovascular-biomarkers-100604459",false,"NCT07149792","A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","SMILE","Inclusion Criteria:\n\n* Healthy subjects\n* Psoriasis patients\n* Psoriatic arthritis patients\n* Agree to provide a blood sample\n\nExclusion Criteria:\n\n* A current history of cancer,\n* Recent hospitalization for infection or current antibiotic treatment\n* HIV infection.",true,"ALL","18 Years","75 Years",{"count":87,"type":88},50,"ESTIMATED","INTERVENTIONAL",[91],"PHASE4","The inclusion criteria for this study were patients aged 18 to 75 years with a confirmed diagnosis of psoriasis by a dermatologist or psoriatic arthritis by a rheumatologist. Patients with active infections or suspected malignancies were excluded.\n\nA total of 40 patients with psoriasis, with or without psoriatic arthritis, were enrolled from multiple centers in Taiwan. All participants were recruited from the outpatient clinics of either the Department of Allergy, Immunology, and Rheumatology or the Department of Dermatology in tertiary hospitals across Taiwan.\n\nParticipants were randomly assigned to one of two groups:\n\nPrescreen Strategy-Based Biologics Selection Group\n\nStandard-Based Biologics Selection Group\n\nPatients will be followed up at weeks 4, 8, 12, 24, 32, 40, 48, 56, 64, and 72. Follow-up may be extended up to 3 years if necessary.\n\nClinical assessments will include:\n\nPrimary endpoints: PASI (Psoriasis Area and Severity Index), painful joint count, swollen joint count, and DAPSA (Disease Activity in Psoriatic Arthritis) score.\n\nSecondary endpoints: DLQI (Dermatology Life Quality Index), BSA (Body Surface Area), pruritus score, and internal carotid artery thickness measured at 6 months, 1 year, and 2 years.",[94,95,96],"Psoriasis","Psoriasis Arthritis","Biologics",[98],"Prescreen, Biologics, Psoriasis, Strategic selection, Psoriatic arthritis","2025-08-24",{"date":101,"type":102},"2025-09-02","ACTUAL",{"date":104,"type":102},"2025-07-29",{"date":106,"type":88},"2028-06-01",{"name":5,"class":6},2]